IFRX vs. SKYE, SBTX, NKTX, NBTX, URGN, QTTB, AVIR, VTYX, KMDA, and LLY
Should you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include Skye Bioscience (SKYE), Silverback Therapeutics (SBTX), Nkarta (NKTX), Nanobiotix (NBTX), UroGen Pharma (URGN), Q32 Bio (QTTB), Atea Pharmaceuticals (AVIR), Ventyx Biosciences (VTYX), Kamada (KMDA), and Eli Lilly and Company (LLY). These companies are all part of the "pharmaceutical preparations" industry.
Skye Bioscience (NASDAQ:SKYE) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment, institutional ownership and community ranking.
Skye Bioscience has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500. Comparatively, InflaRx has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.
21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 0.7% of Skye Bioscience shares are held by insiders. Comparatively, 16.3% of InflaRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Skye Bioscience's return on equity of -37.37% beat InflaRx's return on equity.
Skye Bioscience presently has a consensus target price of $22.00, suggesting a potential upside of 78.86%. InflaRx has a consensus target price of $13.50, suggesting a potential upside of 824.66%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe InflaRx is more favorable than Skye Bioscience.
InflaRx received 231 more outperform votes than Skye Bioscience when rated by MarketBeat users. However, 100.00% of users gave Skye Bioscience an outperform vote while only 64.19% of users gave InflaRx an outperform vote.
In the previous week, Skye Bioscience had 4 more articles in the media than InflaRx. MarketBeat recorded 7 mentions for Skye Bioscience and 3 mentions for InflaRx. Skye Bioscience's average media sentiment score of 0.65 beat InflaRx's score of 0.55 indicating that InflaRx is being referred to more favorably in the news media.
Skye Bioscience has higher earnings, but lower revenue than InflaRx.
Summary
InflaRx beats Skye Bioscience on 10 of the 15 factors compared between the two stocks.
Get InflaRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
